Biovail Financial Statements
Biovail Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Biovail Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 757.2 | 842.8 | 1,070.5 |
| Gross Profit ($ mil.) | 560.0 | 620.9 | 847.2 |
| Operating Income ($ mil.) | 127.9 | 218.5 | 257.5 |
| Total Net Income ($ mil.) | 199.9 | 195.5 | 203.9 |
| Diluted EPS (Net Income) | 1.25 | 1.22 | 1.27 |
Biovail Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 212.5 | 193.5 | 173.3 |
| Gross Profit ($ mil.) | 161.9 | 143.5 | 128.5 |
| Operating Income ($ mil.) | 58.9 | 31.8 | 51.6 |
| Total Net Income ($ mil.) | 40.4 | 24.1 | 39.0 |
| Diluted EPS (Net Income) | 0.25 | 0.15 | 0.25 |
Biovail Stock Quote & Chart
11/06/09 16:02:08 EST •
NYSE •
13.32
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Biovail Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 2.77 | 2.29 | 7.01 |
| Price/Earnings Ratio | 9.42 | 27.32 | 25.51 |
| Price/Book Ratio | 1.63 | 3.43 | 6.74 |
| Price/Cash Flow Ratio | 6.20 | 19.76 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Biovail Financial Ratios
Biovail Competitive Intelligence
| Eli Lilly | Novartis | Teva Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,378.0 | 42,584.0 | 11,085.0 |
| Employees | 40,500 | 96,717 | 38,307 |
| Market Cap ($ mil.) | 39,641.3 | 119,919.4 | 47,451.4 |
Competitive Landscape
